Human Trials

Relief Therapeutics and NeuroRx expand clinical trial of RLF-100 to all patients with critical Covid-19 and respiratory failure

RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that the phase 2/3 clinical trial evaluating RLF-100 as a treatment for Critical COVID-19 with Respiratory Failure has been expanded to include patients receiving high flow oxygen and noninvasive ventilation (CPAP), in addition to those on ventilators. RLF-100 (Aviptadil) is a patented formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which has been granted Orphan Drug Designation by the US FDA in Acute Respiratory Distress Syndrome and chronic lung diseases.

Eli Lilly’s partner Junshi doses first patient in Covid-19 trial with JS016 investigational medicine

Eli Lilly has announced the commencement of a phase 1 study for its second potential Covid-19 antibody treatment.

Alnylam presents positive phase 3 results from ILLUMINATE-A study of Lumasiran

Alnylam Pharmaceuticals announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1).

Calquence showed promising clinical improvement in majority of 19 hospitalised Covid-19 patients

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe Covid-19 disease

Janssen’s TREMFYA delivers improvement in psoriatic arthritis joint and skin symptoms at week 52 in phase 3 trials

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which showed that TREMFYA (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA).

Octapharma USA extends funding for Covid-19 study following positive preliminary research data

Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.

Bristol Myers Squibb announces positive topline results from True North trial evaluating Zeposia in ulcerative colitis

Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.

FSD Pharma gets FDA nod to design Covid-19 trial with ultramicronised PEA

FSD Pharma has secured approval from the US Food and Drug Administration (FDA) to design a phase 2a clinical trial to evaluate the efficacy of FSD-201 (ultramicronised palmitoylethanolamide or ultramicronised PEA) to treat patients with suspected or confirmed Covid-19 diagnosis.

Gilead’s Covid-19 candidate remdesivir delivers positive results in phase 3 trial

Gilead Sciences said that a phase 3 trial with its investigational antiviral remdesivir has delivered positive results in hospitalised patients with moderate Covid-19 pneumonia.